Asked by: Carolyn Harris (Labour - Neath and Swansea East)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, if she will include the British Standard Institution's health and safety document entitled BS 30416 on Menstruation, Menstrual Health and Menopause in the Workplace, published on 31 May 2023, in her Department's guidance on the Employment Rights Act 2025.
Answered by Diana Johnson - Minister of State (Department for Work and Pensions)
We recognise that employers already have access to a wide range of guidance on supporting employees experiencing menopause, including resources produced by the British Standards Institution. While current government guidance does not specifically reference BS 30416: Menstruation, Menstrual Health and Menopause in the Workplace, our aim is to ensure that current and future government advice complements and aligns with such materials.
As part of the Employment Rights Act 2025, this government took the first step towards requiring large employers to publish an action plan detailing what steps they are taking to support employees through the menopause. To support employers to develop these plans, the Office for Equality and Opportunity will provide guidance on recommended actions. This will be drawn from existing evidence, such as DWP's own Menopause in the Workplace Literature Review, while recognising that some actions may also support women managing other reproductive health conditions at work.
Additionally, as part of Government’s wider commitment to Make Work Pay, DWP committed to publishing guidance, including for small employers, on measures to consider relating to uniform and temperature, flexible working and recording menopause-related leave and absence. This is available on the Advisory, Conciliation and Arbitration Service (ACAS): Managing the menopause - Menopause at work - Acas. Actions set out in this guidance are aligned with, and complement, the advice set out in BS 30416 on Menstruation, Menstrual Health and Menopause in the Workplace.
We will keep the evidence base and our guidance under review to ensure it reflects emerging research and best practice in supporting employees experiencing menopause and wider reproductive health conditions.
Asked by: Carolyn Harris (Labour - Neath and Swansea East)
Question to the Wales Office:
To ask the Secretary of State for Wales, what assessment she has undertaken with Cabinet colleagues on the potential impact of granting the Welsh Government’s proposed UK Internal Market Act exemption on the Deposit Return Scheme on (a) businesses and (b) consumers.
Answered by Jo Stevens - Secretary of State for Wales
The Government is following the process to assess the Welsh Government’s proposal for an exclusion from the UK Internal Market Act as set out in the UK Internal Market Act Review published in July 2025. The Government has been engaging with stakeholders to gather evidence and feedback on the impact of the proposal on the UK internal market in order to inform its response to the Welsh Government’s proposal. The Government is working at pace to be able to communicate its position within the Resources & Waste Common Framework, in line with the processes set out in the 2025 Review.
Asked by: Carolyn Harris (Labour - Neath and Swansea East)
Question to the Department for Business and Trade:
To ask the Secretary of State for Business and Trade, what assessment he has made of the potential impact the Welsh Government’s proposed UK Internal Market Act exemption to run its own Deposit Return Scheme would have on (a) existing and (b) future UK trade deals.
Answered by Chris Bryant - Minister of State (Department for Business and Trade)
We have not made such specific assessments, however we are keen to progress a UK Deposit Return Scheme and are currently evaluating the Welsh Government's proposal for an exclusion from the UK Internal Market Act as set out in the UK Internal Market Act Review published in July 2025.
As part of that process we have been engaging with stakeholders to gather evidence and feedback on the impact of the Welsh Government proposal on the UK internal market.
Asked by: Carolyn Harris (Labour - Neath and Swansea East)
Question to the Department for Business and Trade:
To ask the Secretary of State for Business and Trade, whether he has made an assessment of the potential impact of granting the Welsh Government’s proposed UK Internal Market Act exemption on the Deposit Return Scheme on (a) businesses and (b) consumers.
Answered by Chris Bryant - Minister of State (Department for Business and Trade)
We have not made such specific assessments, however we are keen to progress a UK Deposit Return Scheme and are currently evaluating the Welsh Government's proposal for an exclusion from the UK Internal Market Act as set out in the UK Internal Market Act Review published in July 2025.
As part of that process we have been engaging with stakeholders to gather evidence and feedback on the impact of the Welsh Government proposal on the UK internal market.
Asked by: Carolyn Harris (Labour - Neath and Swansea East)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs what assessment she has made of the potential impact of granting the Welsh Government’s proposed UK Internal Market Act exemption to run its own Deposit Return Scheme on food and drink businesses.
Answered by Mary Creagh - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
The Government is following the process to assess the Welsh Government’s proposal for an exclusion from the UK Internal Market Act as set out in the UK Internal Market Act Review published in July 2025. The Government has been engaging with stakeholders to gather evidence and feedback on the impact of the proposal on the UK internal market in order to inform its response to the Welsh Government’s proposal. The Government is working at pace to be able to communicate its position within the Resources & Waste Common Framework, in line with the processes set out in the 2025 Review.
Asked by: Carolyn Harris (Labour - Neath and Swansea East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of potential new treatments for glioblastoma.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care enables research via its research arm, the National Institute for Health and Care Research (NIHR), and is committed to furthering our investment and driving scientific advancements in research into the causes and treatment of brain tumours. Between 2018/19 and 2023/24, the NIHR directly invested £11.8 million in research projects and programmes focused on brain tumours. During the same period, the NIHR’s wider investments include around £37.5 million in research infrastructure and the research workforce. UK Research and Innovation (UKRI), funded by the Department for Science, Innovation and Technology, invested £46.8 million in brain tumour research.
Newly licensed medicines are appraised by the National Institute for Health and Care Excellence (NICE), which is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources.
NICE has issued guidance for the NHS on several treatments for glioma and glioblastoma and has a number of other topics in active development.
Asked by: Carolyn Harris (Labour - Neath and Swansea East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of different funding mechanisms that could be applied to new obesity treatments.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. The NHS in England is legally required to fund medicines recommended in a NICE appraisal, usually within three months of final guidance.
NICE has recommended several weight loss medicines as a clinically and cost-effective use of NHS resources that are now being made available to NHS patients. The NHS is currently rolling out tirzepatide for obesity in primary care, using a phased approach based on clinical need to manage NHS resources. Around 220,000 individuals are expected to be eligible over the next three years. NHS England worked with clinical experts, integrated care boards, patient and public representatives, healthcare professionals, charities and royal colleges on its prioritisation approach, which it set out in its interim commissioning guidance, available at the following link:
Through the Obesity Healthcare Goals programme, launched in 2022, we are working with industry and research partners to develop and test new delivery and funding models. This includes the Obesity Pathway Innovation Programme (OPIP), which is piloting community-based and pharmacy-led provision of weight management services, alongside pharmaceutical and digital interventions. The programme is supported by up to £85 million in joint funding from Government and Eli Lilly, with a portion ring-fenced for devolved administrations. These pilots will generate evidence on clinical outcomes, patient experience, and economic sustainability to inform future commissioning decisions.
The Government remains firmly committed to tackling obesity as a major public health challenge, improving access to effective interventions, and reducing health inequalities across the country.
Asked by: Carolyn Harris (Labour - Neath and Swansea East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of delivering weight management services as part of the neighbourhood health model.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Neighbourhood Health Services will bring together teams of professionals, including nurses, doctors, social care workers, pharmacists, health visitors, and more, closer to people’s homes, to work together to provide comprehensive care in the community.
We expect neighbourhood teams and services to be designed in a way that reflects the specific needs of local populations and so could include weight management services. While the focus on personalised, coordinated care will be consistent, this will mean services will look different, for example in rural communities, coastal towns, and deprived inner cities.
Integrated care boards (ICBs) and local authorities are responsible for commissioning weight management services. We would expect them to commission services based on local population needs, taking account of the National Institute for Health and Care Excellence’s guidelines and the move to a Neighbourhood Health Service.
We are intending to publish a National Framework for Neighbourhood Health Plans in the autumn. This will set out how areas should design neighbourhood health services around local needs and different population cohorts.
Asked by: Carolyn Harris (Labour - Neath and Swansea East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make it his policy to recognise obesity as a disease.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department does not recognise obesity as a disease.
Guidelines from the National Institute for Health and Care Excellence (NICE), which the Government accepts and works to, focus on obesity as a complex but preventable public health issue. NICE does not classify obesity as a disease but recognises that it increases the risks of a range of adverse health outcomes including type 2 diabetes, heart disease, stroke and some cancers. NICE provides robust, evidence-based guidance on the identification, prevention and treatment of obesity. NICE guidelines stress the importance of clinical judgement, including considering whether someone is living with another health condition alongside obesity that may be relevant.
Asked by: Carolyn Harris (Labour - Neath and Swansea East)
Question to the Cabinet Office:
To ask the Minister for the Cabinet Office, what data his Department holds on the number of UK-based distilleries that have (a) opened and (b) closed in each of the last five years.
Answered by Josh Simons - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The information requested falls under the remit of the UK Statistics Authority.
A response to the Hon lady’s Parliamentary Question of 10th October is attached.